Filing Details
- Accession Number:
- 0001610520-24-000153
- Form Type:
- 4/A
- Zero Holdings:
- No
- Publication Time:
- 2024-09-05 15:28:10
- Reporting Period:
- 2024-08-27
- Accepted Time:
- 2024-09-05 15:28:10
- Original Submission Date:
- 2024-08-29
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1681682 | Endra Life Sciences Inc. | NDRA | National Commercial Banks (6021) | V8 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1610520 | Ag Group Ubs | Bahnhofstrasse 45 Zurich V8 CH-8001 | No | No | No | Yes |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-08-27 | 0 | $0.00 | 146,012 | No | 4 | P | Indirect | By Subsidiary |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Indirect | By Subsidiary |
Footnotes
- This Statement is filed jointly by UBS Group AG for the benefit and on behalf of UBS Securities LLC and UBS Financial Services Inc., a wholly owned subsidiary of UBS Group.
- This Form 4 Amendment is being filed to correct and replace the original Form 4 filed on August 29, 2024. Subsequent to the date of first filing, the Reporting Person confirmed directly with the Issuer that, due to certain warrant exercises effected on August 27, 2024, the total outstanding common shares issued by ENDRA Life Sciences as of August 27, 2024 was 16,932,593 shares. When taking the revised share count into consideration, the Reporting Person determined it never beneficially owned more than 10% of ENDRA shares. Therefore the Form 4 previously filed by the Reporting Person was erroneous and unnecessary
Billionaire Hedge Funds
